October 23, 2026) - Global Hemp Group Inc. (CSE: GHG) (FSE: GHG0) (OTC PINK: GBHPF) ("GHG" or the "Company") is pleased to ...

First reported clinical evaluation of an allogeneic CD19-directed CAR T-cell therapy in progressive MS demonstrated an ...

Gilead Sciences has picked up a new inflammatory disease program from China’s PepStar Therapeutics to pair with the Phase 2 ...

A combination of Tango Therapeutics’ vopimetostat and Revolution Medicines’ recently approved Rasonque led to a response rate ...

RNAi specialist Alnylam Pharmaceuticals will advance the Huntington’s disease drug brezosiran into a placebo-controlled study ...

Following the withdrawal of billions of dollars in investments from Boehringer Ingelheim and Eli Lilly, German lawmakers have ...

After cardiac safety signals led to a full clinical hold on Aardvark Therapeutics’ studies of ARD-101, the biotech conducted ...

Financing will support Star’s next phase of growth, including advancement of current preclinical programs into the clinic and ...

Completion of light dose-escalation Part A of Phase 1 study identifies regimen for further evaluation in Part B, supporting ...

MESA, AZ / ACCESS Newswire / October 23, 2026 / Medical Care Technologies Inc. (OTCID:MDCE) today announced that it is ...

(Biokin) reported positive results from a prespecified interim analysis of the randomized Phase 3 PANKU-Breast01 study ...

Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, today ...